These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935 [TBL] [Abstract][Full Text] [Related]
23. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease. Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801 [TBL] [Abstract][Full Text] [Related]
24. Hepatocyte growth factor activator inhibitor type‑1 in cancer: advances and perspectives (Review). Zheng Q; Wu H; Cao J; Ye J Mol Med Rep; 2014 Dec; 10(6):2779-85. PubMed ID: 25310042 [TBL] [Abstract][Full Text] [Related]
25. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Zhou HY; Pon YL; Wong AS Endocrinology; 2007 Nov; 148(11):5195-208. PubMed ID: 17673518 [TBL] [Abstract][Full Text] [Related]
26. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression. Bergum C; List K Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215 [TBL] [Abstract][Full Text] [Related]
27. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Gmyrek GA; Walburg M; Webb CP; Yu HM; You X; Vaughan ED; Vande Woude GF; Knudsen BS Am J Pathol; 2001 Aug; 159(2):579-90. PubMed ID: 11485916 [TBL] [Abstract][Full Text] [Related]
28. Insufficiency of hepatocyte growth factor activator inhibitor-1 confers lymphatic invasion of tongue carcinoma cells. Izumi A; Yamamoto K; Kawaguchi M; Yamashita F; Fukushima T; Kiwaki T; Tanaka H; Yamashita Y; Kataoka H Cancer Sci; 2022 Jun; 113(6):2179-2193. PubMed ID: 35332604 [TBL] [Abstract][Full Text] [Related]
29. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468 [TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cheng H; Fukushima T; Takahashi N; Tanaka H; Kataoka H Cancer Res; 2009 Mar; 69(5):1828-35. PubMed ID: 19223533 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis. Ko CJ; Hsu TW; Wu SR; Lan SW; Hsiao TF; Lin HY; Lin HH; Tu HF; Lee CF; Huang CC; Chen MM; Hsiao PW; Huang HP; Lee MS Oncogene; 2020 Sep; 39(37):5950-5963. PubMed ID: 32778768 [TBL] [Abstract][Full Text] [Related]
32. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247 [TBL] [Abstract][Full Text] [Related]
33. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Nakamura K; Hongo A; Kodama J; Hiramatsu Y Int J Cancer; 2011 Jun; 128(11):2613-24. PubMed ID: 20715109 [TBL] [Abstract][Full Text] [Related]
34. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728 [TBL] [Abstract][Full Text] [Related]
35. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120 [TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2): Emerging key players in epithelial integrity and cancer. Kataoka H; Kawaguchi M; Fukushima T; Shimomura T Pathol Int; 2018 Mar; 68(3):145-158. PubMed ID: 29431273 [TBL] [Abstract][Full Text] [Related]
37. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Harvey P; Clark IM; Jaurand MC; Warn RM; Edwards DR Br J Cancer; 2000 Nov; 83(9):1147-53. PubMed ID: 11027427 [TBL] [Abstract][Full Text] [Related]
38. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277 [TBL] [Abstract][Full Text] [Related]
39. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y Int J Oncol; 2009 Aug; 35(2):239-48. PubMed ID: 19578736 [TBL] [Abstract][Full Text] [Related]
40. KLK14 interactions with HAI-1 and HAI-2 serine protease inhibitors: A molecular dynamics and relative free-energy calculations study. Solís-Calero C; Carvalho HF Cell Biol Int; 2017 Nov; 41(11):1246-1264. PubMed ID: 28817220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]